Skip to main content

Table 2 Adjusted mean change from baseline in total scores on various secondary efficacy outcome measures (LOCF), ITT Population

From: A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

 

Adjusted mean (SE) change from baseline

Secondary outcome

Placebo

Desvenlafaxine 10 mg/d

Desvenlafaxine 50 mg/d

MADRS total score

–9.87 (0.63)

–11.28 (0.63)

–10.76 (0.63)

CGI-S total score

–1.08 (0.07)

–1.23 (0.07)

–1.11 (0.07)

HAM-D6 total score

–4.75 (0.27)

–5.49 (0.27)

–5.19 (0.27)

SDS total score

–2.63 (0.48)

–4.09 (0.48)

–3.78 (0.49)

SDS Work Studies component

–0.61 (0.17)

–1.10 (0.17)

–1.14 (0.17)

SDS Social Life component

–1.08 (0.18)

–1.58 (0.17)

–1.36 (0.18)

SDS Life/Home Responsibilities

–0.98 (0.17)

–1.43 (0.17)

–1.20 (0.17)

WHO-5 total score

2.96 (0.36)

4.51 (0.35)

3.73 (0.36)

  1. p<0.05 and p<0.01; ANCOVA model using treatment as factor and baseline as covariate.
  2. CGI-S, Clinical Global Impressions–Severity; HAM-D6, 6-item Hamilton Rating Scale for Depression; ITT, intent to treat; LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Rating Scale for Depression; SDS, Sheehan Disability Scale; WHO-5, World Health Organization 5-item Well-being Index.